The scramble to research the novel coronavirus has exposed weaknesses in the vetting of health care data being supplied by a growing number of U.S. firms, after a flaw forced two of the most respected medical journals to pull studies last week.
The Lancet and the New England Journal of Medicine (NEJM) retracted COVID-19 studies over questionable patient health data supplied by a small company called Surgisphere.
U.S. researchers say they are routinely peppered with pitches from similar firms, with no widespread standard of how to verify their datasets.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.